News > FDA approves new treatment combination for advanced hormone receptor-positive breast cancer

FDA approves new treatment combination for advanced hormone receptor-positive breast cancer

image_row
A Black woman pouring a pill into her hand
general_content

The combination of giredestrant, an oral selective estrogen receptor degrader (SERD), with everolimus, a drug that targets a protein called mTOR that can help cancer cells grow and spread, worked better in the trial for people with breast cancer that had an ESR1 mutation when compared with standard hormonal therapy plus everolimus.

Participants in the trial had previously been treated with standard hormonal therapies and CDK4/6 inhibitors, but the cancer had continued to grow due mainly to resistance to the hormonal therapies.

An ESR1 mutation develops in about 40% of hormone receptor-positive metastatic breast cancers as a way for the cancer cells to get around standard hormonal therapies. Standard therapies typically lower estrogen in the body or block estrogen from attaching to estrogen receptors to keep the cancer cells from growing. SERDs like giredestrant take things a step further, attaching to the receptors and breaking them down.

The new combination, approved for people with locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer that had an ESR1 mutation that has recurred during or after hormonal therapy-based treatment or progressed after taking at least one hormonal therapy-based treatment, delayed progression or death by 62%.

“This next-generation line of treatment marks real progress for people with advanced breast cancer, giving them more options that offer better quality of life along with controlling their cancer,” says Jean A. Sachs, CEO of Living Beyond Breast Cancer. “In later lines of treatment that often involve infusions and other disruptions to life due to managing MBC, having an all-oral option that people can take from home is a win.”

Giredestrant will also be considered later this month by the FDA for use in people with hormone receptor-positive, HER2-negative early-stage breast cancer at high risk for a recurrence, which would be the first new hormonal therapy for this group in more than 20 years.

related_resources_article_carousel

Related resources

stay_connected

Stay connected

Sign up to receive emotional support, medical insight, personal stories, and more, delivered to your inbox weekly.